Cargando…

Aurora B expression modulates paclitaxel response in non-small cell lung cancer

BACKGROUND: Taxanes are mitotic poisons widely used in the treatment of non-small cell lung cancer (NSCLC), however, little is known about potential molecular modulators of response to these compounds. Aurora B (AURKB) is a critical regulator of the mitotic spindle assembly, previously shown overexp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Khafaji, Ahmed SK, Davies, Michael PA, Risk, Janet M, Marcus, Michael W, Koffa, Maria, Gosney, John R, Shaw, Richard J, Field, John K, Liloglou, Triantafillos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344288/ https://www.ncbi.nlm.nih.gov/pubmed/28095398 http://dx.doi.org/10.1038/bjc.2016.453

Ejemplares similares

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing
por: Shaw, Richard J., et al.
Publicado: (2006)

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
por: Schmidt, M, et al.
Publicado: (2007)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death
por: Obiorah, I, et al.
Publicado: (2014)

Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
por: Yang, Q, et al.
Publicado: (2014)

(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
por: Sereni, Maria Isabella, et al.
Publicado: (2017)

A leukotriene B(4) receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells
por: Kim, H, et al.
Publicado: (2013)

COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer
por: Oleksiewicz, Urszula, et al.
Publicado: (2017)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling
por: Wei, L-H, et al.
Publicado: (2007)

Irreversible electroporation on the small intestine
por: Phillips, M A, et al.
Publicado: (2012)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
por: Overman, M J, et al.
Publicado: (2010)

Cancer cell proliferation is inhibited by specific modulation frequencies
por: Zimmerman, J W, et al.
Publicado: (2012)

Treatment decisions and survival for people with small-cell lung cancer
por: Powell, H A, et al.
Publicado: (2014)

Modulating cancer cell survival by targeting intracellular cholesterol transport
por: Kuzu, Omer F, et al.
Publicado: (2017)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Interleukin-10-regulated tumour tolerance in non-small cell lung cancer
por: Vahl, Julius Malte, et al.
Publicado: (2017)

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
por: Jiang, P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3f7s7cghj5tvkiurm092kqs9ni